Board Members 2025-2026

C. Anthony Altar, PhD, Splice Therapeutics

Enrique Carrazana, MD, Neurelis

Amy Chappell, MD

Gail Farfel, PhD, Board Director, Neurvati/GRIN Therapeutics and the Dravet Syndrome Foundation

Kazuo Fujihara, MD, Fukushima Medical University School of Medicine

Dietrich Haubenberger, MD, Neurocrine Biosciences

Aditya Joshi, MD, University of Pennysylvania

Kenneth Sommerville, MD

Sharon Tamir, Mitsubishi Tanabe Pharma America

Tom Sutula, MD, PhD (Past President), University of Wisconsin

Andrew Cole, MD (Past President), Harvard Medical School

Ludy Shih, MD, MMSc (President), Harvard Medical School

Maral Mouradian, MD, Rutgers Robert Wood Johnson Medical School (Editor-In-Chief, ex officio)

Amir Tamiz, PhD, National Institutes of Neurological Disorders and Stroke (ex officio)

Scientific Program Committee Members 2025-2026

C. Anthony Altar, PhD, Splice Therapeutics

Deena Andreola, Takeda Pharmaceuticals

Suhayl Dhib-Jalbut, MD, Rutgers Robert Wood Johnson Medical School

Gail Farfel, PhD, Board Director, Neurvati/GRIN Therapeutics and the Dravet Syndrome Foundation

Marjan Gharagozloo, PhD, Johns Hopkins University

Aditya Joshi, MD, University of Pennysylvania (Chair)

A. Michelle Manzo, MPH, Xenon Pharmaceuticals

Yazmin Odia, MD, Louisiana State University

Parisa Sanandaji, Stoke Therapeutics

Nancy Santilli

Sean Savitz, MD, University of Texas Health Science Center at Houston

Ludy Shih, MD, MMSc, Harvard Medical School (Co-chair)

Sharon Tamir, Mitsubishi Tanabe Pharma America

Debra Ehrlich, MD, National Institutes of Neurological Disorders and Stroke (ex officio)

Amir Tamiz, PhD, National Institutes of Neurological Disorders and Stroke (ex officio)